EnVivo Pharmaceuticals, Inc. Announces Neuropharmacology Publication, Confirms Novel Mechanism of Action of Lead Program EVP-6124
12/13/2011 7:16:19 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced data published in the peer-reviewed journal Neuropharmacology confirming the novel mechanism of action of its lead program EVP-6124. EnVivo has demonstrated that EVP-6124 is a potent and highly selective agonist of alpha-7 neuronal nicotinic acetylcholine receptors (nAChRs) in the brain and that treatment with EVP-6124, both alone and in combination with donepezil, restored memory loss and improved memory function in preclinical models. These findings further support the company’s clinical development strategy for EVP-6124 as a long-term treatment to restore and improve cognitive function with sustained effect in schizophrenia and Alzheimer’s disease.